Spyre Therapeutics

We are excited to share that Spyre was recognized by Fortune as one of the Top 30 Best Workplaces in Biopharma for 2024! At Spyre, we hold ourselves to the highest standard of performance while pursuing our mission to improve the lives of those living with IBD. Congratulations to the team! To view the full list of Fortune’s Best Workplaces visit: https://lnkd.in/e77AfHjA #GreatPlacesToWork #Biotech #IBD

We're #hiring a new Senior Manager, Regulatory Operations in United States. Apply today or share this post with your network.

We're #hiring a new Principal Medical Writer in United States. Apply today or share this post with your network.

Today, we announced an acceleration of our third program, SPY003 (anti-IL-23), which is now expected to enter a Phase 1 clinical trial in Q1 2025. We also announced presentations of scientific posters this past weekend at the UEG - United European Gastroenterology Week (UEGW) Congress, including new data across our portfolio of next-generation antibodies and potentially paradigm-changing combination therapies. For more information, you can read the full news release and forward-looking statement legend here: https://lnkd.in/g6uKbiPb Scientific posters can be viewed here: https://lnkd.in/gYpHiq2g #IBD #BioTech

We're #hiring a new Associate Director, Data Management in United States. Apply today or share this post with your network.

We are excited to share the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer of Spyre. Dr. Sloan has over 25 years of experience in both large pharmaceutical and small biotech companies and an extensive track record of program leadership in the field of inflammation and immunology. We are grateful to have Dr. Sloan on board as we continue our efforts to advance each of our programs into the clinic and initiate Phase 2 studies in 2025. Please join us in welcoming Dr. Sloan to Spyre! Read the full news here: https://lnkd.in/gbV4h6FP #IBD #BioTech

We're #hiring a new Senior Clinical Trial Manager, Clinical Operations in United States. Apply today or share this post with your network.

Today, Spyre is attending the Stifel 2024 Virtual Immunology and Inflammation Summit. Spyre management will participate in a virtual fireside chat and investor meetings to discuss upcoming milestones and our progress in advancing treatment for those living with IBD. To watch a replay of the webcast, head to ir.spyre.com. #IBD

We're #hiring a new Associate Director, Regulated Bioanalysis in United States. Apply today or share this post with your network.

We're #hiring a new Senior Manager, Finance in United States. Apply today or share this post with your network.